Please assess the completion status of the following clinical trial:

Trial Title: Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven and inoperable advanced gastric adenocarcinoma.~2. Bi-dimensionally measurable disease by physical examination or image study (roentgenogram or computed tomography scan). The index lesions should be at least 20 mm × 10 mm in size.~3. Age must be older than 18 and younger than 75 year-old.~4. Karnofsky performance status\>60% (see Appendix)~5. Adequate bone marrow reserves, defined as white blood cell (WBC)\>4,000/l, absolute neutrophil count (ANC)\>1,500/l, platelet\>100,000/l.~6. Liver transaminases \<2.5 times upper normal limit if no liver metastasis and 5 times upper normal limit if liver metastasis is present; total bilirubin \<1.5 mg/dl; serum creatinine\<1.5mg/dl.~7. Serum triglyceride level\>70mg/dl.~8. Previous chemotherapy for metastatic disease is not allowed in this study. Previous adjuvant chemotherapy following curative gastrectomy is acceptable if the adjuvant chemotherapy has been completed for more than 6 months before enrollment into the present study.~9. Previous radiotherapy is allowed if the treatment was completed at least 4 weeks before the enrollment into this study.~10. Patients of childbearing age should have effective contraception during the study period.~11. All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional guidelines.~Exclusion Criteria:~1. Patients who are receiving concurrent radiotherapy, chemotherapy or other experimental therapy.~2. Patients who refuse port-A catheter implantation.~3. Patients with brain or leptomeningeal metastases.~4. Patients who have significant cardiac arrhythmia or acute myocardial infarction within 6 months before entry.~5. Patients who have major systemic diseases that the attending physicians considered inappropriate for systemic chemotherapy.~6. Life expectancy of less than 2 months.~7. Pregnant or nursing women may not participate. Women or men with reproductive potential may not participate unless they have agreed to use an effective contraceptive method.~8. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancers, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any cancer from which the patient has been disease-free for 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).